Pain In The (ER) Battlefield: AcelRx Reports Positive ARX-04 Results

AcelRx reports fast-acting, pain-reducing data for ARX-04 in emergency room-treated trauma patients, which is the setting that most closely resembles battlefield situations experienced by personnel in the US military – the Phase III program's co-funder.

chemistry

The US military kicked in $17m to support the Phase III development of AcelRx Pharmaceuticals Inc.'s ARX-04 and the most recently reported data for the fast-acting pain drug seem to show that it could meet the specialty customer's needs for the product.

The military did not require a single-arm, open-label clinical trial in the emergency room setting, but study is the closest...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Business

More from Scrip